BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31056428)

  • 21. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
    Stubbins RJ; Korotev S; Godley LA
    Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic mutation panels: Time to clear their names.
    Trottier AM; Cavalcante de Andrade Silva M; Li Z; Godley LA
    Cancer Genet; 2019 Jun; 235-236():84-92. PubMed ID: 31101556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic TP53 variants frequently confound germ-line testing results.
    Weitzel JN; Chao EC; Nehoray B; Van Tongeren LR; LaDuca H; Blazer KR; Slavin T; Facmg DABMD; Pesaran T; Rybak C; Solomon I; Niell-Swiller M; Dolinsky JS; Castillo D; Elliott A; Gau CL; Speare V; Jasperson K
    Genet Med; 2018 Aug; 20(8):809-816. PubMed ID: 29189820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
    BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
    Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
    Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort.
    Kraemer D; Azzarello-Burri S; Steindl K; Boonsawat P; Zweier M; Dedes KJ; Joset P; Fink D; Rauch A
    Swiss Med Wkly; 2019 Aug; 149():w20092. PubMed ID: 31422574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
    Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
    Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
    Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
    Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
    Hoffman TL; Kershberg H; Goff J; Holmquist KJ; Haque R; Alvarado M
    Fam Cancer; 2023 Apr; 22(2):225-235. PubMed ID: 36261688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
    Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma.
    Abdel-Rahman MH; Sample KM; Pilarski R; Walsh T; Grosel T; Kinnamon D; Boru G; Massengill JB; Schoenfield L; Kelly B; Gordon D; Johansson P; DeBenedictis MJ; Singh A; Casadei S; Davidorf FH; White P; Stacey AW; Scarth J; Fewings E; Tischkowitz M; King MC; Hayward NK; Cebulla CM
    Ophthalmology; 2020 May; 127(5):668-678. PubMed ID: 32081490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
    Pearlman R; Frankel WL; Swanson B; Zhao W; Yilmaz A; Miller K; Bacher J; Bigley C; Nelsen L; Goodfellow PJ; Goldberg RM; Paskett E; Shields PG; Freudenheim JL; Stanich PP; Lattimer I; Arnold M; Liyanarachchi S; Kalady M; Heald B; Greenwood C; Paquette I; Prues M; Draper DJ; Lindeman C; Kuebler JP; Reynolds K; Brell JM; Shaper AA; Mahesh S; Buie N; Weeman K; Shine K; Haut M; Edwards J; Bastola S; Wickham K; Khanduja KS; Zacks R; Pritchard CC; Shirts BH; Jacobson A; Allen B; de la Chapelle A; Hampel H;
    JAMA Oncol; 2017 Apr; 3(4):464-471. PubMed ID: 27978560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ATM whole gene deletion in an Italian family with hereditary pancreatic cancer: Challenges to cancer risk prediction associated with an 11q22.3 microdeletion.
    Arts HH; Lynch L; Grafodatskaya D; Eng B; Malloy L; Duck J; White R; Woodside C; Bell K; Zbuk KM; McCready E
    Cancer Genet; 2020 Jan; 240():1-4. PubMed ID: 31671381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.